<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12554">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00474851</url>
  </required_header>
  <id_info>
    <org_study_id>07-01-0004</org_study_id>
    <nct_id>NCT00474851</nct_id>
  </id_info>
  <brief_title>The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial</brief_title>
  <official_title>The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Boston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Boston</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a regimen of norethindrone acetate +
      placebo or norethindrone acetate + conjugated estrogens is superior in maintaining skeletal
      health and quality of life in adolescents treated with a GnRH agonist for endometriosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endometriosis has become increasingly recognized as a chronic illness which begins during
      adolescence. Untreated endometriosis may lead to chronic pain and infertility. As
      recognition of the need for prompt therapy increases, so does the length of time patients
      will be exposed to treatments. As a result, there exists a pressing need to evaluate
      adjunctive measures that may limit the associated negative health consequences of treatment.

      A gonadotropin-releasing hormone (GnRH) agonist is one medication utilized for patients who
      have failed other treatments. While GnRH-agonists are effective in relieving symptoms, their
      long-term use is problematic. GnRH agonists induce a low-estrogen state, causing deleterious
      effects on bone mineralization. These negative consequences are especially important for our
      pediatric patients. Adolescence is the critical period in a woman's life for bone
      acquisition and attainment of peak bone mass. Anything that interferes with this process
      puts patients at risk for lifelong low bone density and future fracture.

      &quot;Add-back&quot; therapy appears to be a promising adjunct to treatment for prevention of this
      bone loss. Daily therapy with low-doses of hormones preserves bone density in adult
      patients, without altering the efficacy of the GnRH-agonist. However, no data exist on the
      effect of add-back therapy in adolescents.

      The aim of the current study is to evaluate the safety and efficacy of two add-back
      regimens, norethindrone acetate + placebo or norethindrone acetate + conjugated estrogens,
      for the preservation of skeletal health and quality of life in adolescents with
      endometriosis treated with a GnRH-agonist.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Bone Mineral Density</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adjusted mean change in total body areal bone mineral density (aBMD) over the 12 month trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Body Bone Mineral Content (BMC)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Norethindrone acetate + estrogens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the experimental arm received add-back therapy with norethindrone acetate 5 mg by mouth daily + conjugated equine estrogens 0.625 mg by mouth daily for the 12 months of study participation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>norethindrone acetate + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to the experimental arm received add-back therapy with norethindrone acetate 5 mg by mouth daily + a placebo capsule by mouth daily for the 12 months of study participation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norethindrone acetate + estrogens</intervention_name>
    <description>Norethindrone acetate 5 mg by mouth daily + Conjugated equine estrogens 0.625 mg by mouth daily</description>
    <arm_group_label>Norethindrone acetate + estrogens</arm_group_label>
    <other_name>Aygestin</other_name>
    <other_name>Premarin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>norethindrone acetate + placebo</intervention_name>
    <description>norethindrone acetate 5 mg by mouth daily + Placebo capsule 1 pill by mouth daily</description>
    <arm_group_label>norethindrone acetate + placebo</arm_group_label>
    <other_name>Aygestin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 13-22 years, at least two years post-menarche

          -  Body mass index (BMI, kg/m2) between 18 -30 kg/m2

          -  Surgical diagnosis of endometriosis

          -  Clinical decision to treat with a GnRH agonist, leuprolide depot (Lupron DepotÂ®; TAP
             Pharmaceuticals, Inc.) 11.25 mg intra-muscular every 3 months

        Exclusion Criteria:

          -  Concomitant chronic diseases which affect bone health, such as cystic fibrosis,
             inflammatory bowel disease, renal disease, or diabetes mellitus

          -  Markedly impaired liver function or liver failure

          -  Personal history of thromboembolic event (such as deep venous thrombosis)

          -  Medication use known to affect bone metabolism:

               -  Glucocorticoid therapy (including inhaled steroids) or anticonvulsants used in
                  the last 6 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy D DiVasta, MD, MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Boston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 17, 2015</lastchanged_date>
  <firstreceived_date>May 15, 2007</firstreceived_date>
  <firstreceived_results_date>March 4, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Boston</investigator_affiliation>
    <investigator_full_name>Amy DiVasta</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Endometriosis</keyword>
  <keyword>Adolescents</keyword>
  <keyword>Bone density</keyword>
  <keyword>GnRH Agonist</keyword>
  <keyword>Add-back therapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention Group</title>
          <description>Conjugated equine estrogens: Conjugated estrogens 0.625 mg PO daily
Norethindrone acetate: Norethindrone acetate 5 mg PO daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Placebo group
Placebo: Placebo capsule 1 pill PO daily
Norethindrone acetate: Norethindrone acetate 5 mg PO daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Baseline</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention Group</title>
          <description>Conjugated equine estrogens: Conjugated estrogens 0.625 mg PO daily
Norethindrone acetate: Norethindrone acetate 5 mg PO daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Placebo: Placebo capsule 1 pill PO daily
Norethindrone acetate: Norethindrone acetate 5 mg PO daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="51"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="17.7" spread="1.4"/>
                <measurement group_id="B2" value="18.1" spread="1.9"/>
                <measurement group_id="B3" value="17.9" spread="1.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="51"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="51"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="49"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="51"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density</title>
        <description>Adjusted mean change in total body areal bone mineral density (aBMD) over the 12 month trial</description>
        <time_frame>Baseline to 12 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Conjugated equine estrogens: Conjugated estrogens 0.625 mg PO daily
Norethindrone acetate: Norethindrone acetate 5 mg PO daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo group
Placebo: Placebo capsule 1 pill PO daily
Norethindrone acetate: Norethindrone acetate 5 mg PO daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Bone Mineral Density</title>
            <description>Adjusted mean change in total body areal bone mineral density (aBMD) over the 12 month trial</description>
            <units>g/cm^2</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.01" spread="0.006"/>
                  <measurement group_id="O2" value="-0.11" spread="0.006"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis followed the intention-to-treat principle. The time course of each measurement from baseline to 3, 6, 9, and 12 months was compared between arms by repeated-measures analysis of variance (RM-ANOVA), with an autoregressive covariance model to account for visit-to-visit correlation within subjects.
The primary test of treatment efficacy was time Ã treatment interaction. Adjusted changes over time and differences between trial arms were constructed from parameters of the RMANOVA.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.10</p_value>
            <p_value_desc>p (within group for subjects receiving norethindrone + conjugated estrogens)=0.05 p (within group for subjects receiving norethindrone + placebo)=0.65 p (between the two groups)=0.10</p_value_desc>
            <method>RMANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Bone Mineral Content (BMC)</title>
        <time_frame>Baseline to 12 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Conjugated equine estrogens: Conjugated estrogens 0.625 mg PO daily
Norethindrone acetate: Norethindrone acetate 5 mg PO daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo: Placebo capsule 1 pill PO daily
Norethindrone acetate: Norethindrone acetate 5 mg PO daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Total Body Bone Mineral Content (BMC)</title>
            <units>g</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37" spread="10"/>
                  <measurement group_id="O2" value="15" spread="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The time course of each measurement from baseline to 3, 6, 9, and 12 months was compared between arms by repeated-measures analysis of variance (RM-ANOVA), with an autoregressive covariance model to account for visit-to-visit correlation within subjects.
The primary test of treatment efficacy was time Ã treatment interaction. Adjusted changes over time and differences between trial arms were constructed from parameters of the RMANOVA.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.02</p_value>
            <p_value_desc>p (within group for participants receiving norethindrone + estrogens)=0.0001 p (within group for participants receiving norethindrone + placebo)=0.31 p (between groups)=0.02</p_value_desc>
            <method>RMANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were evaluated every 3 months (at every research visit) for a total of 12 months (the duration of study participation).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention Group</title>
          <description>Conjugated equine estrogens: Conjugated estrogens 0.625 mg PO daily
Norethindrone acetate: Norethindrone acetate 5 mg PO daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Placebo group
Placebo: Placebo capsule 1 pill PO daily
Norethindrone acetate: Norethindrone acetate 5 mg PO daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <description>Bone fractures, secondary to fall or trauma. Non spontaneous, not low impact</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for pelvic/abdominal pain</sub_title>
                <description>All events determined to be likely due to flare of subject's underlying disease, endometriosis</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgias/arthralgias</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <description>Pain that did not require hospitalization or surgery</description>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vaginal bleeding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sample of skeletally mature young women; Measurements of aBMD are two-dimensional and do not yield information regarding skeletal strength or microarchitecture</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Amy D. DiVasta</name_or_title>
      <organization>Boston Children's Hospital</organization>
      <phone>617-355-3792</phone>
      <email>Amy.DiVasta@childrens.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
